RIGL Q2 2019 Earnings — Rigel Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

RIGLRigel Pharmaceuticals, Inc.

$517M

Q2 2019 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$10M+482.4% YoY

Gross Profit

$10M97.0% margin

Operating Income

-$21M-205.0% margin

Net Income

-$21M-198.0% margin

EPS (Diluted)

$-1.23

QoQ Revenue Growth

-17.6%

Cash Flow

Operating Cash Flow

-$17M

Free Cash Flow

-$17M

Stock-Based Comp.

$3M

Balance Sheet

Total Assets

$156M

Total Liabilities

$78M

Stockholders' Equity

$78M

Cash & Equivalents

$44M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$10M	$2M	+482.4%
Gross Profit	$10M	$2M	+474.6%
Operating Income	-$21M	-$26M	+18.3%
Net Income	-$21M	-$26M	+19.4%

Revenue Segments

Gross Product

$12M49%

Product

$10M40%

License

$4M18%

Contract Revenues From Collaborations

$234,0001%

Research And Development Services

$234,0001%

Discounts And Allowances

-$2M-9%